Journal of Oncology / 2019 / Article / Fig 5

Research Article

Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer

Figure 5

Anti-DCLK1 mAbs inhibit pancreatic cancer xenograft tumor growth. (a) Biweekly injection of CBT-15 mAb (i.p.) significantly impairs SW1990 pancreatic cells originated tumor xenograft growth (p<0.0001) as confirmed by (b) decreased excised tumor volume and (c) decreased excised tumor mass. (d) Biweekly injection of CBT-15X mAb (i.p.) significantly impairs SW1990 (solid line with solid squares) and AsPC-1 (dashed line with solid squares) pancreatic cells originated tumor xenograft growth (p<0.005) as confirmed by (e) decreased excised tumor mass.

(a)
(b)
(c)
(d)
(e)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.